SunTrust Banks set a $172.00 price target on Alexion Pharmaceuticals (NASDAQ:ALXN) in a report issued on Monday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.
A number of other research analysts also recently issued reports on ALXN. Piper Jaffray Companies reiterated an overweight rating and set a $170.00 price objective on shares of Alexion Pharmaceuticals in a report on Monday, October 23rd. Stifel Nicolaus decreased their price objective on Alexion Pharmaceuticals from $165.00 to $159.00 and set a buy rating for the company in a report on Tuesday, October 24th. Royal Bank of Canada increased their price objective on Alexion Pharmaceuticals to $166.00 in a report on Tuesday, October 24th. Zacks Investment Research raised Alexion Pharmaceuticals from a hold rating to a buy rating and set a $144.00 price target for the company in a research report on Tuesday, October 31st. Finally, TheStreet cut Alexion Pharmaceuticals from a b- rating to a c+ rating in a research report on Friday, November 10th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and twenty-one have issued a buy rating to the stock. The company has a consensus rating of Buy and an average price target of $152.77.
Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) opened at $115.43 on Monday. Alexion Pharmaceuticals has a fifty-two week low of $96.18 and a fifty-two week high of $149.34. The stock has a market capitalization of $24,074.60, a PE ratio of 58.89, a price-to-earnings-growth ratio of 0.95 and a beta of 1.16. The company has a quick ratio of 2.62, a current ratio of 3.10 and a debt-to-equity ratio of 0.34.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.09 by $0.39. Alexion Pharmaceuticals had a return on equity of 12.94% and a net margin of 12.48%. The company had revenue of $909.70 million during the quarter, compared to the consensus estimate of $880.38 million. During the same period in the prior year, the company earned $1.26 earnings per share. The company’s revenue for the quarter was up 9.5% compared to the same quarter last year. sell-side analysts predict that Alexion Pharmaceuticals will post 6.25 EPS for the current fiscal year.
In other news, CEO Ludwig Hantson sold 13,245 shares of the stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $116.31, for a total transaction of $1,540,525.95. Following the transaction, the chief executive officer now owns 131,425 shares in the company, valued at $15,286,041.75. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Paul J. Clancy sold 6,079 shares of the stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $116.31, for a total value of $707,048.49. Following the transaction, the chief financial officer now owns 95,093 shares in the company, valued at approximately $11,060,266.83. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 28,930 shares of company stock valued at $3,378,199. Insiders own 4.35% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in ALXN. Jennison Associates LLC increased its stake in shares of Alexion Pharmaceuticals by 720.0% during the third quarter. Jennison Associates LLC now owns 5,332,636 shares of the biopharmaceutical company’s stock worth $748,116,000 after purchasing an additional 4,682,336 shares during the period. Assenagon Asset Management S.A. increased its stake in shares of Alexion Pharmaceuticals by 4,509.0% during the third quarter. Assenagon Asset Management S.A. now owns 884,150 shares of the biopharmaceutical company’s stock worth $124,037,000 after purchasing an additional 864,967 shares during the period. Alkeon Capital Management LLC bought a new position in shares of Alexion Pharmaceuticals during the third quarter worth approximately $70,145,000. Wells Fargo & Company MN increased its stake in shares of Alexion Pharmaceuticals by 32.7% during the third quarter. Wells Fargo & Company MN now owns 1,558,531 shares of the biopharmaceutical company’s stock worth $218,647,000 after purchasing an additional 383,713 shares during the period. Finally, Pictet Asset Management Ltd. increased its stake in shares of Alexion Pharmaceuticals by 46.7% during the third quarter. Pictet Asset Management Ltd. now owns 1,126,275 shares of the biopharmaceutical company’s stock worth $158,005,000 after purchasing an additional 358,695 shares during the period. Institutional investors own 94.01% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Alexion Pharmaceuticals (ALXN) Given a $172.00 Price Target by SunTrust Banks Analysts” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another domain, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/02/13/alexion-pharmaceuticals-alxn-given-a-172-00-price-target-by-suntrust-banks-analysts.html.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.